STM STMicroelectronics NV

Unique Nu Eyne Wearable Eye-Therapy Device Leverages STM32 Wireless Microcontroller from STMicroelectronics

Unique Nu Eyne Wearable Eye-Therapy Device Leverages STM32 Wireless Microcontroller from STMicroelectronics

Unique Nu Eyne Wearable Eye-Therapy Device

Leverages STM32 Wireless Microcontroller from STMicroelectronics

MCU-controlled eyewear promotes efficient tissue regeneration

and treats dry eye



Geneva, Switzerland and Seoul, Korea, September 29, 2021 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, and Nu Eyne, Korea’s innovative medical device manufacturer, have jointly announced a Nu Eyne wearable therapy device for eye care powered by an STM32WB55* dual-core Bluetooth® LE (BLE) microcontroller (MCU).

Nu Eyne’s recently launched CELLENA wearable device utilizes electric current and light emitted to the eyes and associated nerves to relieve eye dryness and fatigue, as well as to promote healthy retinal functions. Durable and light for everyday use, the device supports multiple therapy sessions on a single charging cycle and records and stores product-usage logs. A mobile application will be released soon for greater user convenience and interactive therapy management.

The CELLENA device relies on the dual-core architecture of the STM32WB55 MCU for reliable wireless connectivity and real-time processing. With its embedded security features, ST’s MCU also delivers multiple security mechanisms, including user data protection and encrypted firmware update over BLE. The STM32WB55’s ultra-low-power performance also significantly extends battery runtime of Nu Eyne’s wearable eye-therapy.

“The wireless performance of the STM32WB55 MCU inside CELLENA exceeded our expectations and made it easier to focus on our primary objective of delivering a product to promote tissue regeneration and relieve dry eyes and pain, said Joowan Seo, Director of Technology and Engineering, Nu Eyne. “All Nu Eyne products are powered by MCUs from ST, which enables us to promptly integrate new STM32 chips in our designs using the easy-to-use STM32 development software. We have chosen ST for their consistent and reliable high-quality products and technical support. ST actively engages with their partners to find solutions from the early stages of development.”

“Nu Eyne’s decision to rely on STM32 wireless MCUs for their innovative wearable eye-therapy device is a perfect example of our life.augmented mission to use technology to make a positive contribution to people’s lives,” said Arnaud Julienne, Vice President, Head of Marketing and Applications of MDG, IoT/AI Competence Center and Digital Marketing, Asia Pacific Region, STMicroelectronics. “This collaboration with Nu Eyne demonstrates the tremendous potential of STM32WB MCUs for the healthcare market, where security, together with high performance and low power, is essential.

*STM32 is a registered and/or unregistered trademark of STMicroelectronics International NV or its affiliates in the EU and/or elsewhere. In particular, STM32 is registered in the US Patent and Trademark Office.

About STMicroelectronics

At ST, we are 46,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An independent device manufacturer, we work with more than 100,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of the Internet of Things and 5G technology. Further information can be found at .

About NUEYNE

Nu Eyne is a medical R&D company that focuses on utilizing electroceuticals technology to treat various chronic diseases. For the past three years, we had been validating the safety and efficacy of treatment concepts in our pre-clinical animal studies, as well as from clinical trials with university-hospitals. Our targeting indications are as follows: dry eye disease, retinal dystrophies, migraine, facial palsy, ADHD, and ASD. We are also pioneering in the electroceuticals technology by focusing on novel anti-cancer treatment protocols with a wearable device and an artificial retina implant device for vision restoration. Further information can be found at

For Press Information Contact:



Laney Lee

Press Officer, Korea

STMicroelectronics

Tel:

Email:

Attachments



EN
29/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STMicroelectronics NV

 PRESS RELEASE

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program STMicroelectronics Announces Status ofCommon Share Repurchase Program Disclosure of Transactions in Own Shares – Period from August 18, 2025 to August 22, 2025 AMSTERDAM – August 25, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder ...

 PRESS RELEASE

STMicroelectronics Publishes its IFRS 2025 Semi Annual Accounts

STMicroelectronics Publishes its IFRS 2025 Semi Annual Accounts PR No. C3355C STMicroelectronics Publishes its IFRS 2025 Semi Annual Accounts Geneva, August 20, 2025 – STMicroelectronics NV (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, published today its IFRS 2025 Semi Annual Accounts for the six-month period ended June 28, 2025, on its website and filed them with the Netherlands Authority for the Financial Markets (AFM). The Company’s Semi Annual Accounts, prepared in accordance with International Financial Reporti...

 PRESS RELEASE

STMicroelectronics publie son rapport financier IFRS pour le premier s...

STMicroelectronics publie son rapport financier IFRS pour le premier semestre 2025 PR No. C3355C STMicroelectronics publie son rapport financier IFRS pour le premier semestre 2025 Genève, le 20 août 2025 – STMicroelectronics NV (NYSE : STM), un leader mondial des semiconducteurs dont les clients couvrent toute la gamme des applications électroniques, annonce ce jour la publication de son rapport financier IFRS pour le premier semestre 2025, clos le 28 juin 2025, sur son site web. Le rapport a été enregistré auprès de l’ « Authority for Financial Markets » néerlandaise (AFM). Le r...

 PRESS RELEASE

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program STMicroelectronics Announces Status ofCommon Share Repurchase Program Disclosure of Transactions in Own Shares – Period from August 11, 2025 to August 15, 2025 AMSTERDAM – August 18, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder ...

 PRESS RELEASE

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program STMicroelectronics Announces Status ofCommon Share Repurchase Program Disclosure of Transactions in Own Shares – Period from August 4, 2025 to August 8, 2025 AMSTERDAM – August 11, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch